Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry-Reference-Cited by-同舟云学术

Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Published:2023-12-22 Issue: Volume: Page:
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Iaffaldano Pietro,Lucisano Giuseppe,Guerra Tommaso,Patti Francesco,Cocco Eleonora,De Luca Giovanna,Brescia Morra Vincenzo,Pozzilli Carlo,Zaffaroni Mauro,Ferraro Diana,Gasperini Claudio,Salemi Giuseppe,Bergamaschi Roberto,Lus Giacomo,Inglese Matilde,Romano Silvia,Bellantonio Paolo,Di Monte Elisabetta,Maniscalco Giorgia Teresa,Conte Antonella,Lugaresi Alessandra,Vianello Marika,Torri Clerici Valentina Liliana Adriana,Di Sapio Alessia,Pesci Ilaria,Granella Franco,Totaro Rocco,Marfia Girolama Alessandra,Danni Maura Chiara,Cavalla Paola,Valentino Paola,Aguglia Umberto,Montepietra Sara,Ferraro Elisabetta,Protti Alessandra,Spitaleri Daniele,Avolio Carlo,De Riz Milena,Maimone Davide,Cavaletti Guido,Gazzola Paola,Tedeschi Gioacchino,Sessa Maria,Rovaris Marco,Di Palma Franco,Gatto Maurizia,Cargnelutti Daniela,De Robertis̄ Francesca,Logullo Francesco Ottavio,Rini Augusto,Meucci Giuseppe,Ardito Bonaventura,Banfi Paola,Nasuelli Davide,Paolicelli Damiano,Rocca Maria Assunta,Portaccio Emilio,Chisari Clara Grazia,Fenu Giuseppe,Onofrj Marco,Carotenuto Antonio,Ruggieri Serena,Tortorella Carla,Ragonese Paolo,Nica Mihaela,Amato Maria Pia,Filippi Massimo,Trojano Maria^ORCID,

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-023-12137-8.pdf

Reference36 articles.

1. Filippi M, Danesi R, Derfuss T et al (2022) Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol 269(3):1670–1677. https://doi.org/10.1007/s00415-021-10836-8

2. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis. EMA/CHMP/771815/2011, https://www.ema.europa.eu/en/documents/scientific-guideline/guidelineclinical-investigation-medicinal-productstreatment-multiple-sclerosis_en-0.pdf

3. Bayas A, Christ M, Faissner S et al (2023) Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis—a review of population-specific evidence from randomized clinical trials. Ther Adv Neurol Disord. https://doi.org/10.1177/17562864221146836. (Published 2023 Jan 24)

4. Gross RH, Corboy JR (2019) Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies [published correction appears in Continuum (Minneap Minn). 2019 Aug;25(4):1175]. Continuum (Minneap Minn). 25(3):715–735. https://doi.org/10.1212/CON.00000000000007383

5. Ziemssen T, Derfuss T, de Stefano N et al (2016) Optimizing treatment success in multiple sclerosis. J Neurol 263(6):1053–1065. https://doi.org/10.1007/s00415-015-7986-y

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palliative Care Aspects in Multiple Sclerosis;Journal of Pain and Symptom Management;2024-01